NCT05549037View on ClinicalTrials.gov

Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC

PHASE3RecruitingINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

December 2, 2024

Study Completion Date

December 31, 2025

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Pembrolizumab, Sintilimab

One for morning group, the patients in this group were treated with immunochemotherapy before 15:00. One for afternoon group, the patients in this group were treated with immunochemotherapy after 15:00.

Trial Locations (1)

410013

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Province Tumor Hospital

OTHER